Kashmira Gander

By Kashmira Gander

Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


A British man taking part in a COVID-19 vaccine trial has revealed the potential side effects of the shot include a fever "at worst."

Simeon Courtie, an author and former children's TV presenter, is taking part in a trial being run by the University of Oxford's Jenner Institute and Oxford Vaccine Group. Starting Friday, phase one of the trial will test whether the vaccine is safe to use in healthy volunteers, and enable researcher to see if it generates an immune response. There are 500 people taking part in the trial, Courtie told Good Morning Britain.

Courtie said he was told the side effects would be "something along the lines of having flu." As everyone is reacts differently the severity will vary, he said. "I think at worst maybe a fever for a couple of days and some aches and pains. It shouldn't be too disruptive to my life."

Read More

Coronavirus Could Be Here ‘Permanently,’ Says Top Adviser to U.K. Government8 min read

Coronavirus Could Be Here ‘Permanently,’ Says Top Adviser to U.K. Government

Testing Sewage for Coronavirus Could Help Predict Future COVID-19 Outbreaks, Scientists Believe7 min read

Testing Sewage for Coronavirus Could Help Predict Future COVID-19 Outbreaks, Scientists Believe

Coronavirus Stayed in Woman’s Eyes for 20 Days6 min read

Coronavirus Stayed in Woman’s Eyes for 20 Days

Courtie has attended the Jenner Institute in Oxford for screenings, and will have his first dose next Wednesday, he said.

Ohid Yaqub, senior lecturer at the Science Policy Research Unit at the University of Sussex who is not working on the study, said in a statement, "the vaccine they are testing is a small part of the COVID virus, packaged inside a delivery vector, neither of which can cause disease but may be successful in triggering an immune response."

Yaqub said: "The trial will mostly be looking for any problems or severe adverse reactions. There will very likely be none, so the trial is also designed to enable us to learn a little bit about efficacy at the same time."

There is currently no vaccine or specific treatment for COVID-19, which has killed over 184,000 people, according to Johns Hopkins University. More than 2.6 million people have been diagnosed with COVID-19, and at least 721,531 have recovered. As the graph by Statista below shows, the U.S. is the county with the most known cases.

There are over 100 potential vaccines in development around the world, with the Oxford group among the first to test theirs in human volunteers.

statista, covid19, coronavirus,

...

Yaqub said: "In terms of broader policy context, this is extremely early days. We should be careful not to tempt people working on vaccines into estimating or making optimistic predictions about when a vaccine will be ready. There is a long history of over-optimistic vaccine predictions.

"Even if a vaccine unexpectedly becomes available, it is too early even to speculate whether it will have high efficacy or low efficacy. A low efficacy vaccine will have different policy implications in terms of how it should be rolled out.

"I therefore think public policy attention should continue to focus on testing and on healthcare system capacity, and should focus on lockdown and managing the social costs of (partial) lockdown for as long as possible."

Centers for Disease Control and Prevention Advice on Using Face Coverings to Slow Spread of COVID-19

World Health Organization advice for avoiding spread of coronavirus disease (COVID-19)

Hygiene advice

Medical advice

Mask and glove usage

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines